Morphic — Investor Presentation (September 2020)
22 slides from Morphic's investor presentation, Sep 23, 2020
Slide 1: Delivering a New Generation of Integrin Medicines
DELIVERING A NEW GENERATION OF INTEGRIN MEDICINES October 2020
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward - looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Morphic’s or our partners’ plans to develop and commercialize oral small - m
Slide 3: Morphic: Cracking the Code of Oral Integrin Therapies
3 Morphic : "Cracking the Code" of Oral Integrin Therapies Unique MInT Platform to Interrogate the Integrin Target Class Lead Asset in IBD Targeting Validated Biology in Blockbuster Space Broad Preclinical Pipeline Addressing Multiple Disease Areas Partnerships with Marquee Pharmaceutical Companies
Slide 4: The Integrin Receptor: Vast Biologic and Therapeutic Potential
The Integrin Receptor: Vast Biologic and Therapeutic Potential 4 Extracellular matrix Cytoskeleton Expensive, complicated biologics have proven the blockbuster value of integrin inhibitors But efforts to create small molecule drugs to realize this promise have failed for 30 years Family of cell surf
Slide 5: Morphic Integrin Technology (MInT) Platform: Building Knowledge Through Iteration
Morphic Integrin Technology (MInT) Platform: Building Knowledge Through Iteration J Cell Biol, 2012 5 α 4 β 7 α v β 6 α v β 8 α v β 1 MInT Platform
Slide 6: Morphic: A Deep Proprietary & Partnered Pipeline
Status Target (Program) Indication Preclinical Terms Partner α v β 6 ( MORF - 720 & MORF - 627) Idiopathic pulmonary fibrosis and fibrotic diseases AbbVie paid $100M for exclusive option to multiple targets, $20M to exercise α v β 6 option Undisclosed targets Fibrotic diseases Undisclosed targets Ca
Slide 7: Targeting α4β7, a validated mechanism, for Inflammatory Bowel Disease
MORF - 057 Targeting α 4 β 7 , a validated mechanism, for Inflammatory Bowel Disease 7 α 4 β 7
Slide 8: Highly Selective Oral Inhibitor for Inflammatory Bowel Disease
Highly Selective Oral α 4 β 7 Inhibitor for Inflammatory Bowel Disease 8 MORF - 057 MECHANISM INDICATIONS SUPPORTING DATA CLINICAL PLANS Highly selective orally available small molecule inhibitor of α 4 β 7 A safe, oral IBD treatment is needed and c ould address the need for safe and effective oral
Slide 9: α4β7 Inhibition is a Proven Mechanism to Treat IBD
Approved antibody Entyvio® (vedolizumab) Sub - endothelial space - gut Vascular space - blood T - cell a 4 b 7 MAdCAM - 1 Endothelial cell • α 4 β 7 + T - cells are trafficked to gut tissue via MAdCAM - 1 binding. These T - cells cause inflammation that leads to inflammatory bowel disease. • Vedoliz
Slide 10: MORF-057 Has Inherently High Selectivity for α4β7 Versus Other Integrins
MORF - 057 Has Inherently High Selectivity for α 4 β 7 Versus Other Integrins 10 α 4 β 7 MAdCAM - 1 α 4 β 1 Endothelial cell Leukocyte Inhibiting VCAM - 1 brings risk of PML VCAM - 1 • MORF - 057 is highly selective for α 4 β 7 over α 4 β 1 in cell adhesion assays in 50% human serum (over 3 orders o
Slide 11: MORF-057: Dose-dependent Anti-inflammatory Activity Comparable to Anti-α4β7 mAb
MORF - 057: Dose - dependent Anti - inflammatory Activity Comparable to Anti - α 4 β 7 mAb in Pre - clinical Studies 11 • p<0.05, ** p<0.01, ***p<0.001, and ****p<0.0001 vs. vehicle by One Way Anova followed by Dunnett’s multiple comparisons % of CFSE+ in T - cells MORF - 057, mpk mLN **** **** ****
Slide 12: MORF-057 and Related Compounds Impact Tmem Biomarker in a Dose-dependent Manner
MORF - 057 and Related Compounds Impact T mem Biomarker in a Dose - dependent Manner 12 The biomarker response with MR - 5288 (closely related tool compound of MORF - 057) is dose responsive Means and SD of data normalized per individual at timepoint 0h (first dose administration). T test analysis w
Slide 13: Morphic Oral Inhibitor Saturates Receptor in Non-human Primate Study
Morphic Oral Inhibitor Saturates α 4 β 7 Receptor in Non - human Primate Study 13 • Mn - free RO assay ( ex vivo whole blood) using a multimeric, MAdCAM - based probe enables physiologically relevant RO measurements • Range of % RO for all animals at all timepoints post first dose is 90.4 to 100%. R
Slide 14: MORF-057: Phase 1 Trial with Biomarkers Provides Opportunity for Early Proof of Concept
MORF - 057: Phase 1 Trial with Biomarkers Provides Opportunity for Early Proof of Concept 14 1. SAD cohort: safety, tolerability, and PK/PD 2. Food Effect Cohort to determine PK of a single, projected clinically relevant dose 3. MAD cohort: safety, tolerability, and PK/PD, including receptor occupan
Slide 15: Proprietary Pipeline
Proprietary Pipeline 15 α v β 8 Creating the next generation of proprietary integrin inhibitor candidates α v β 1 α 4 β 7 α 4 β 7
Slide 16: αvβ1 Inhibition: Potential to Treat Fibrosis Across Multiple Organ Systems
Latent TGF - β Active TGF - β α v β 1 TGF - β activation Fibrogenesis Chronic injury α v β 1 Inhibition: Potential to Treat Fibrosis Across Multiple Organ Systems α v β 1 inhibition is believed to block the activation of latent TGF - β , leading to the reduction of collagen depositions that drive fi
Slide 17: αvβ8 Small Molecule Inhibitor Enhances Checkpoint Inhibitor Response in Immune Excluded Model
αv β 8 Small Molecule Inhibitor Enhances Checkpoint Inhibitor Response in Immune Excluded Model αv β 8 inhibition blocks activation of TGF - b, a key regulator of tumor formation, progression, and metastasis EMT6 Murine Breast Cancer Model EMT - 6 inoculation on day 0. Dosing window days 6 through 2
Slide 18: Partnered Programs
Partnered Programs Leveraging the MInT platform to create new oral integrin candidate for premier collaborators 18 α v β 6
Slide 19: Platform-validating Partnerships
Platform - validating Partnerships 19 • $100 million upfront partnership agreement to develop multiple selective orally available small molecule integrin inhibitors • Initial focus on α v β 6 inhibition to prevent TGF - β activation and collagen deposition leading to fibrosis • AbbVie exercised $20
Slide 20: Deep Specialist Expertise Across Management and Board of Directors
Deep Specialist Expertise Across Management, and Board of Directors PRAVEEN TIPIRNENI, MD President and Chief Executive Officer BRUCE ROGERS, PhD Chief Scientific Officer ALEXEY A. LUGOVSKOY, PhD Chief Development Officer MARC SCHEGERIN, MD Chief Financial Officer Chief Operating Officer PETER LINDE
Slide 21: Morphic: Cracking the Code of Oral Integrin Therapies
21 Morphic : "Cracking the Code" of Oral Integrin Therapies Unique MInT Platform to Access the Integrin Target Class Lead Asset in IBD Targeting Validated Biology in Blockbuster Space Broad Preclinical Pipeline Addressing Multiple Disease Areas Partnerships with Marquee Pharmaceutical Companies Stro
Slide 22: Delivering a New Generation of Integrin Medicines
DELIVERING A NEW GENERATION OF INTEGRIN MEDICINES
Morphic Holding — Investor Presentation (September 2020) on 6ix